NCT01905228已完成1 期
A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm
Incuron4 个研究点 分布在 1 个国家目标入组 83 人开始时间: 2013年7月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 83
- 试验地点
- 4
- 主要终点
- Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)
研究概览
简要总结
This is an open-label, multi-center, sequential groups, dose-escalation study of CBL0137 administered intravenously in participants with metastatic or unresectable advanced solid malignancies.
详细描述
The primary objective of the study is to determine the maximally tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of CBL0137. The secondary objectives are to describe the dose-limiting toxicity (DLT) and adverse event profile of CBL0137, to describe the pharmacokinetic profile of CBL0137, to document any objective responses to CBL0137. This is a study of CBL0137 with a standard "3+3" design. Escalation will proceed to the MTD based on DLT in the 1st cycle in 1 of 6 participants in a cohort.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 15 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have histological or cytological evidence of a solid neoplasm
- •Patients enrolled in the expansion cohort must have at least one measureable lesion as defined by the RECIST 1.1 criteria for patients with systemic tumors or the RANO criteria for patients with gliomas;
- •Patients with a systemic tumor must:
- •have metastatic or unresectable advanced solid tumors that have recurred or progressed following standard therapy or
- •no longer be candidates for standard therapy or
- •have tumors for which there is no standard therapy
- •Patients with a glioma must:
- •have Grade III (anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic oligoastrocytoma) disease, Grade IV (glioblastoma) disease, or diffuse intrinsic pontine glioma (DIPG) and;
- •have received prior therapy including radiation and drug therapy and;
- •have documented recurrent disease as defined in the RANO criteria;
- •Patients must be ambulatory and have an ECOG Performance Score of 0 or 1;
- •Patients or their legal representative must be able to provide written informed consent;
- •Patients must have adequate bone marrow reserve as evidenced by:
- •White Blood Cell Count (WBC) > 3,000/µL
- •Absolute Neutrophil Count (ANC) > 1,500/µL
- •Platelet count (PLT) > 75,000/µL
- •Hemoglobin (HGB) > 8.0 gm/dL (patients may be transfused to achieve this HGB level);
- •Patients must have adequate hepatic function as evidenced by:
- •Serum AST/ALT < 3X the upper limit of normal (ULN) for the reference lab (< 5X the ULN for patients with known hepatic metastases)
- •Serum bilirubin < 1.5 x the ULN for the reference lab;
排除标准
- •Patients with active infection or with a fever > 38.50 C within 3 days of the first scheduled day of dosing;
- •Patients with symptomatic CNS metastases who have not undergone surgery and/or radiotherapy and/or who are not neurologically stable;
- •Patients with known hypersensitivity to any of the components of CBL0137;
- •Patients who are receiving concurrent anticancer therapy;
- •Patients receiving enzyme-inducing antiepileptic agents within 14 days prior to the start of study therapy;
- •Males with mean QTcF values of > 450 msec and females with QTcF values of > 470 msec following 3 ECGs conducted 5 minutes apart from each other; patients who are known to have congenital prolonged QT syndromes; or patients who are on medications known to cause prolonged QT intervals on ECG;
- •Please speak with the PI for the complete Inclusion/Exclusion listing.
研究组 & 干预措施
CBL0137
Experimental
- Dose Level 9: 150 mg/m2, IV
- Dose Level 10: 180 mg/m2, IV
- Dose Level 11: 240 mg/m2, IV
- Dose Level 12: 320 mg/m2, IV
- Dose Level 13: 400 mg/m2, IV
- Dose Level 14: 540 mg/m2, IV
- Dose Level 15: 700 mg/m2, IV
- Dose Level 16: 920 mg/m2, IV
- Dose Level 17: 1200 mg/m2, IV
- Dose Level 18: 1600 mg/m2, IV
- Dose Level 19: 2100 mg/m2, IV
- Dose Level 20: 2700 mg/m2, IV
干预措施: CBL0137 (Drug)
结局指标
主要结局
Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)
时间窗: At the end of Cycle 1 (each cycle is 28 days)
MTD is defined as dose level at which ≥6 participants have been treated and which is associated with a first-cycle DLT in ≤17% of the participants. Selection of RP2D from within the tolerated dose range will be based on evaluation of short- and long-term safety information together with findings relating to compliance, pharmacokinetics, pharmacodynamics and antitumor activity.
次要结局
未报告次要终点
研究者
研究点 (4)
Loading locations...
相似试验
招募中
1 期
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and LymphomaMetastatic Malignant Neoplasm in the Central Nervous SystemRecurrent Diffuse Intrinsic Pontine GliomaRecurrent LymphomaRecurrent Primary Malignant Central Nervous System NeoplasmRefractory Malignant Solid NeoplasmRefractory Primary Malignant Central Nervous System NeoplasmNCT04870944Children's Oncology Group63
终止
1 期
CBL0137 in Treating Patients With Advanced Extremity Melanoma or SarcomaAdvanced Cutaneous Melanoma of the ExtremityAdvanced Sarcoma of the ExtremityClinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Pathologic Stage IIIB Cutaneous Melanoma AJCC v8Pathologic Stage IIIC Cutaneous Melanoma AJCC v8Pathologic Stage IV Cutaneous Melanoma AJCC v8Recurrent Cutaneous Melanoma of the ExtremityRecurrent Sarcoma of the ExtremityStage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8Stage IIIA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8Stage IIIB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8NCT03727789Roswell Park Cancer Institute7
已完成
1 期
Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal MalignanciesAdvanced Nonhematological MalignanciesNon-Small Cell Lung CancerHead and Neck Squamous Cell CarcinomaGastroesophageal AdenocarcinomaMetastatic Breast CancerSmall Cell Lung CancerNCT01045421Millennium Pharmaceuticals, Inc.273
进行中（未招募）
1 期
Phase I/IIa Study of BR1733 in Subjects With Advanced CancersAdvanced CancerPeripheral T Cell LymphomaDiffuse Large B Cell LymphomaFollicular LymphomaNCT05749549Shanghai Blueray Biopharma Co., Ltd.191
暂停
1 期
A Dose Escalation Study of E7107 Administered Intravenously on Days 1 and 8 Every 21 Days to Patients With Solid TumorsCancerNCT00499499Eisai Inc.40